in vivo CAR-T cell therapy / Fortress, Mayo Clinic - LARVOL DELTA

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "Mustang continues to collaborate with the Mayo Clinic to progress our exclusively licensed novel in vivo CAR-T technology platform that may be able to transform the administration of CAR-T therapies and has the potential to be used as an off-the-shelf therapy. Mustang anticipates the publication of proof-of-concept research in a murine tumor model in 2024."

Preclinical • Oncology

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (Fortress Biotech Press Release) - "We continue to collaborate with the Mayo Clinic to potentially revolutionize the delivery of CAR T in patients. The technology has the potential to generate CAR T cells within the patient’s body after two outpatient injections, without the need for traditional ex vivo allogeneic or autologous CAR T cell processing wait time and expense. We anticipate the publication of proof-of-concept research from in vivo animal studies in 2023."

Preclinical • Oncology

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "Mustang continues to collaborate with the Mayo Clinic to progress its exclusively licensed novel in vivo CAR T technology platform that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the-shelf therapy. Mustang anticipates the publication of proof-of-concept research in a murine tumor model in 2023."

Preclinical • Oncology

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones (GlobeNewswire) - "The Safety Review Team ('SRT') composed of Investigators and Mustang representatives recently met to assess the progress and safety data from the ongoing Mustang-sponsored, open label, multicenter Phase 1/2 clinical trial to evaluate the safety and efficacy of MB-102 in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm ('BPDCN'), a rare form of leukemia….The MB-102 clinical trial is the first under Mustang’s IND in which a patient was dosed with cells processed in its own manufacturing facility. In 2023, Mustang expects to provide information about Dose Level 2 after that level is fully enrolled and the SRT has reviewed the data....Published proof-of-concept data from murine tumor model studies are anticipated in 2023. Additionally, Mustang plans to file an IND application for a multicenter Phase 1 clinical trial once a lead CAR construct has been identified."

IND • P1/2 data • Hematological Malignancies • Leukemia • Oncology